News

Marker Therapeutics lands $16.2M Texas grant for cancer cell therapy

What's the deal? Marker TherapeuticsDealroom has a profile for this one. Try Dealroom → (Nasdaq: MRKR) has won a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT)Dealroom has a profile for this one. Try Dealroom →. The non-dilutive funding will support the planned Phase 2 APOLLO study of its lead therapy, MT-601, for patients with relapsed or refractory large B-cell lymphoma.

What's the endgame? Marker is a clinical-stage immuno-oncology company developing multi-antigen recognising (MAR)-T cell therapies under a worldwide license from Baylor College of Medicine. MT-601 targets patients who relapse after CD19-directed CAR-T cell treatment — a group with few options and poor outcomes.

Why now? The grant builds on Phase 1 data reported in August 2025: a 66% objective response rate and a 50% complete response rate among 12 evaluable patients with non-Hodgkin lymphoma. Some responses lasted up to 24 months, with no dose-limiting toxicities recorded. Marker expects updated clinical results later this year.

How competitive was it? CPRIT received 207 applications this cycle and awarded $74.3 million to 12 projects. The program, backed by the State of Texas, screens for scientific merit, regulatory strategy, manufacturing feasibility, and commercial potential.

"Securing this $16.2 million award from CPRIT is an important milestone for Marker," said Juan Vera, president and chief executive officer. He said the funding provides "meaningful external recognition of our differentiated MAR-T cell approach."

Geoffrey Shouse, principal investigator at City of Hope National Medical Center, said patients who relapse after CAR-T therapy "continue to face limited treatment options and poor clinical outcomes."

The signal: At $16.2 million, the award ranks near the top of US health-sector grants — above the 96th percentile among more than 7,000 comparable rounds. For a small-cap biotech, non-dilutive state funding offers a way to advance a late-stage trial without tapping public markets.

Read more: morningstar.com

Image credit: Generated with Gemini

More top stories